Cite
HARVARD Citation
Sotiriou, C. et al. (n.d.). 1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. European journal of cancer. pp. S269-. [Online].